Coagulation Analyzer Market – Development Of High-Sensitivity PoC Coagulation Testing Will Boost the Growth of This Market
The coagulation analyzer market is projected to reach USD 4.84 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 10.2% from 2016 to 2021.
Currently, point-of-care (PoC) devices are available
in the market and provide rapid bedside monitoring to aid clinicians in
directing appropriate targeted therapy. Majority of POC devices used
today can perform multiple coagulation tests and provide high
sensitivity, improved patient compliance, and decreased testing
turnaround time (compared to laboratory testing coagulation analyzers)
for the diagnosis and management of blood disorders. Consequently, the
demand for POC testing coagulation analyzers is increasing across the
globe.
Due to technological advancements, dual- and
four-channel systems that can be simultaneously used for testing of PT,
APTT, ACT, and fibrinogen testing, have been launched in the market.
Moreover, technological advancements in point-of-care procedures along
with quality assurance and home testing services are anticipated to gear
up the market growth over the forecast period. Driven by the increasing
demand for PoC testing, several players are focusing on the development
of PoC coagulation analyzers.
Key players in the single-cell analysis market are
Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche
Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation
(Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France),
Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and
International Technidyne Corporation (U.S.).
Comments
Post a Comment